RFA-HL-24-010: The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $150,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 2, 2023.
From the official notice on Grants.gov, last changed June 21, 2023. Checked November 7, 2026.
- Award ceiling$150,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG1
- Clinical trialsOptional
- Funded byNHLBI
- Median yearly award$233,250
- Typical project length29 years
Projects funded under RFA-HL-24-010 were run by National Heart Lung and Blood Institute (NHLBI, 19 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-24-010 in the NIH Guide.
Key dates
| Posted | June 20, 2023 |
|---|---|
| Deadline | October 2, 2023 |
| Archived by Grants.gov | November 7, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $233,250; it allows up to $150,000 per award.
- Most of the program's money (57% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with R01-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed.
Funded under RFA-HL-24-010 so far
NIH funded 19 projects under RFA-HL-24-010 in fiscal 2024 to 2026, at 19 institutions. The median yearly award was $233,250.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| BMT CTN Core - City of Hope National Medical Center | Beckman Research Institute/City of Hope | 2026 | $264,000 |
| BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN) | University of Michigan at Ann Arbor | 2026 | $223,829 |
| BMT Core- The Ohio State University blood and marrow transplant research consortium | Ohio State University | 2026 | $219,365 |
| BMT CTN Core - University of Minnesota | University of Minnesota | 2026 | $232,500 |
| BMT CTN Core: Baylor College of Medicine Consortium | Baylor College of Medicine | 2026 | $230,545 |
| Blood and Marrow Transplant Clinical Trials Network | Duke University | 2026 | $236,935 |
| Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | H. Lee Moffitt Cancer Ctr & Res Inst | 2026 | $214,179 |
| BMT Core: Southeast Bone Marrow Transplant Consortium | Emory University | 2026 | $227,631 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-24-010 still open?
No. It closed on October 2, 2023.
Who can apply for The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional)?
Closed October 2, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $150,000 each.
Who has been funded under RFA-HL-24-010?
NIH RePORTER lists 19 projects funded under RFA-HL-24-010 in fiscal 2024 to 2026, at 19 institutions. The most were at Beckman Research Institute/City of Hope, University of Michigan at Ann Arbor, Ohio State University.
Who has won Cancer Treatment Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai. The program made 3,622 awards worth $5.6 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)